Trial Profile
An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Trabectedin (Primary)
- Indications Liposarcoma; Sarcoma
- Focus Pharmacodynamics
- 13 Oct 2023 According to Janssen Pharmaceuticals media release, Janssen Pharmaceuticals has changed its name to Johnson & Johnson Innovative Medicine
- 06 Sep 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 20 Jun 2019 Status changed from suspended to recruiting.